by Daniel Schwartz | Sep 25, 2023 | Guidance for Patients, PHSP
Access to Care Reducing the Cost of Pharmaceuticals in Canada Canada is well-known for its universal healthcare system, which provides all citizens and permanent residents with access to medically necessary hospital and physician services without direct charges at the...
by Daniel Schwartz | Dec 14, 2022 | Guidance for Patients
CLINICAL TRIALS TIPS for STARTING AN SGLT2 inhibitor SGLT2i inhibitors (eg empagliflozin, dapagliflozin, canagliflozin) have a phenomenal evidence base and have been shown to be beneficial in diabetes, heart disease (particularly heart failure) and kidney disease....
Recent Comments